No Picture
News

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

FRISCO, Texas, May 31, 2022 /PRNewswire/ — Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on the ongoing first-in-human clinical trial of […]

No Picture
News

L7 Informatics and Triumvira Immunologics Announce Agreement to Digitalize Manufacturing of Next-Generation Cell Therapies

Clinical-stage biotech to implement a unified platform with a single data fabric versus point solutions AUSTIN, Texas, May 31, 2022 /PRNewswire/ — L7 Informatics, the leader in DATA+INTELLIGENCE for the scientific enterprise, and Triumvira Immunologics […]

No Picture
News

Orthofix M6-C Artificial Cervical Disc IDE Study Data to be Presented at ISASS Demonstrates Continued Statistically Significant Benefits at Five Years

LEWISVILLE, Texas–(BUSINESS WIRE)–Five year data shows M6-C patients continue to have significant benefits in neck disability and shoulder/arm pain scores compared to ACDF patients. Click here to view original post